Short term treatment of mild to moderate pain associated with extra articular inflammation. Symptomatic treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. Approximately 16% of patients (in case of long term treatment 20 – 25%) can be expected to experience adverse reaction concerning the gastrointestinal tract, 5% concerning the general disorders andor central nervous system disorders, and 2% concerning the skin.